An experimental vaccine is set to be tested in Indonesia to prevent viral hepatitis symptoms.
The new vaccine will be given to a select group of people to try and block viral transmission, said Riziequr Rahman, director of the World Health Organization (WHO) vaccine research unit in Geneva.
The vaccine will also be used to vaccinate those suffering from viral hepatitis.
The vaccine is based on the work of Professor Mohammad Abdi, who has also led studies on viral hepatitis in South Korea, Bangladesh and the Philippines.
The virus is not a pandemic.
The WHO is still evaluating the vaccine’s safety, but said it is likely to be effective in preventing viral hepatitis after two to three months.
“In general, we would expect the vaccination to reduce the risk of transmission to people who are infected but who do not develop the symptoms,” said Dr. Rajesh Pathan, WHO director of vaccine safety.
The vaccine was approved in December, but is only one part of a global vaccine effort to vaccine more than 60 million people to reduce global infection rates.
The United States is the only country that has yet to start a vaccine trial.
“We are really happy that the vaccine is going to be available in Indonesia,” Abdi told Reuters in a phone interview.
Dr. Abdi said that Indonesia had a very low viral hepatitis rate in the past.
“They have a high rate of infection,” he said.
In the past, Indonesians have received two to five shots of the vaccine per year.